CDEK
← All drugs Report issue

relatlimab

Trade name: Opdualag

mAbapprovedFast Track FDA

Approved

Mar 18, 2022

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. — Wikipedia

Clinical trial activity

67 trials · 40 clinical orgs · 1 marketing orgs

Phase 1
18
Phase 2
53
Phase 3
11
Phase 4
0

Earliest trial started Apr 10, 2018 (NCT03470922)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Bristol-Myers Squibb — Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Bristol-Myers Squibb — Earliest Phase 3 Sponsor(trial)

  2. Mar 18, 2022

    Bristol-Myers Squibb — Earliest FDA Approval

  3. Mar 18, 2022

    Bristol-Myers Squibb — Marketing Organization

  4. Mar 18, 2022

    Bristol-Myers Squibb — NDA Secondary Org

  5. Mar 18, 2022

    Bristol-Myers Squibb — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

  • opdualag

    with nivolumab

    Also known as nivolumab and relatlimab-rmbw

Approval history

  • approvedFast trackMar 18, 2022

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

First in class

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06999980Phase 2Dec 31, 2025Bristol-Myers Squibb, Melanoma Institute Australia
NCT07281924Phase 1/Phase 2 (Phase 2)Dec 31, 2025Delcath Systems, University of Wisconsin
NCT06963905Phase 1/Phase 2 (Phase 2)Nov 30, 2025Bristol-Myers Squibb, Yale University
NCT06816927Phase 2Jun 1, 2025Duke University
NCT06325683Phase 2May 31, 2025National Cancer Institute (NCI)
NCT06708949Phase 2May 1, 2025Bristol-Myers Squibb, University of Texas at Houston
NCT06683755Phase 1/Phase 2 (Phase 2)May 1, 2025University of Texas at Houston
NCT06880549Phase 1Mar 25, 2025Moderna Therapeutics
NCT06697197Phase 1/Phase 2 (Phase 2)Mar 3, 2025Bristol-Myers Squibb
NCT06712927Phase 2Feb 28, 2025Stanford University
NCT06743126Phase 3Dec 31, 2024immatics Biotechnologies GmbH
NCT06624644Phase 2/Phase 3 (Phase 3)Nov 30, 2024Linnaeus Therapeutics, Inc., Merck
NCT06319196Phase 2Nov 30, 2024University of Toronto
NCT06715241Phase 2Nov 29, 2024ARCAGY-GINECO
NCT06624475Phase 2Oct 31, 2024Bristol-Myers Squibb, University of California, San Diego
NCT06561386Phase 3Oct 7, 2024Bristol-Myers Squibb
NCT06246916Phase 3Sep 9, 2024Regeneron
NCT06288191Phase 2Jul 31, 2024Bristol-Myers Squibb, Melanoma Institute Australia
NCT06264180Phase 3Jul 11, 2024Replimune Inc.
NCT06295159Early Phase 1 (Phase 1)May 17, 2024Bristol-Myers Squibb, University of South Florida
Showing 20 of 67 trials
Page 1 / 4

Organizations

Research & Development (40)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit411942018
National Cancer Institute (NCI)Government5422018
Johns Hopkins UniversityAcademic/Hospital4422018
Melanoma Institute AustraliaAcademic/Hospital4412022
University of Texas at HoustonAcademic/Hospital4412022
University of PittsburghAcademic/Hospital3312019
MerckFor profit2022020
Netherlands Cancer InstituteAcademic/Hospital2212021
University of Duisburg-EssenAcademic/Hospital2212019
University of South FloridaAcademic/Hospital2212023
ARCAGY-GINECOFor profit1112024
Delcath SystemsFor profit1012025
Department of DefenseGovernment1012020
Duke UniversityAcademic/Hospital1112025
ECOG-ACRIN Cancer Research GroupAcademic/Hospital1012022
GWT-TUD GmbHFor profit1012019
immatics Biotechnologies GmbHFor profit1112024
Immunocore LtdFor profit1112023
Institut BergoniéAcademic/Hospital1112019
IO BiotechFor profit1012023
40 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
Bristol-Myers SquibbFor profitMKTGMar 18, 2022
Bristol-Myers SquibbFor profitNDA2Mar 18, 2022
Bristol-Myers SquibbFor profitNDAMar 18, 2022